Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 randomized trial of sugammadex dosing by actual vs ideal body weight in morbidly obese adults
2017-000188-33Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2017
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of Sugammadex in reversal of nondepolarizing neuromuscular blockade and general anesthesia (3 arms), sponsored by Merck & Co. Primary endpoint: Time to recovery to TOF ratio ≥0.9 (ABW vs IBW sugammadex dosing, pooled across depth of block and NMBA). Started Sep 2017; status: completed.
02
Drugs
Sugammadex
03
Conditions
reversal of nondepolarizing neuromuscular blockadegeneral anesthesia
Beyond the preview
Go deeper on 2017-000188-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000188-33.